GE HealthCare Technologies Inc. (BVC:GEHCCO)
Colombia · Delayed Price · Currency is COP | Market Cap | 108.28T -17.5% |
| Revenue (ttm) | 76.80T +6.0% |
| Net Income | 6.99T -12.6% |
| EPS | 15,264.74 -12.4% |
| Shares Out | n/a |
| PE Ratio | 15.50 |
| Forward PE | 12.62 |
| Dividend | 537.88 (0.21%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 2 |
| Average Volume | 4 |
| Open | n/a |
| Previous Close | 255,000 |
| Day's Range | n/a |
| 52-Week Range | 252,380 - 331,660 |
| Beta | n/a |
| RSI | 32.68 |
| Earnings Date | Apr 29, 2026 |
About BVC:GEHCCO
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, an... [Read more]
Financial Performance
In 2025, BVC:GEHCCO's revenue was $20.63 billion, an increase of 4.84% compared to the previous year's $19.67 billion. Earnings were $2.08 billion, an increase of 4.57%.
Financial numbers in USD Financial StatementsNews
GE HealthCare highlights next-generation SIGNA MR systems
GE HealthCare (GEHC) announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful cl...
GE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact
CHICAGO--(BUSINESS WIRE)--As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (Nasdaq: ...
GE HealthCare Technologies Transcript: AGM 2026
The meeting reviewed strong 2025 financials, robust innovation investments, and strategic segment changes. All director nominees and proposals passed, with ongoing mitigation of tariffs and inflation highlighted as key challenges. Demand remains strong across global markets.
GE HealthCare Technologies Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GE HealthCare Technologies Inc. (NASDAQ: GEHC). The investigation focuses...
GE HealthCare price target lowered to $85 from $89 at Oppenheimer
Oppenheimer analyst Suraj Kalia lowered the firm’s price target on GE HealthCare (GEHC) to $85 from $89 and keeps an Outperform rating on the shares following quarterly results. The firm…
GE HealthCare price target lowered to $80 from $85 at Evercore ISI
Evercore ISI lowered the firm’s price target on GE HealthCare (GEHC) to $80 from $85 and keeps an Outperform rating on the shares.
GE HealthCare price target lowered to $65 from $80 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on GE HealthCare (GEHC) to $65 from $80 and keeps a Neutral rating on the shares.
GE HealthCare price target lowered to $65 from $80 at Citi
Citi lowered the firm’s price target on GE HealthCare (GEHC) to $65 from $80 and keeps a Neutral rating on the shares.
GE HealthCare price target lowered to $78 from $87 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on GE HealthCare (GEHC) to $78 from $87 and keeps an Equal Weight rating on the shares. The company reported a…
GE HealthCare downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst David Roman downgraded GE HealthCare (GEHC) to Neutral from Buy with a price target of $65, down from $81, following the Q1 report. The company’s reduced 2026E…
GE HealthCare price target lowered to $65 from $80 at Citi
Citi lowered the firm’s price target on GE HealthCare (GEHC) to $65 from $80 and keeps a Neutral rating on the shares. Expectations were low going into the print, but…
GE HealthCare price target lowered to $80 from $98 at Stifel
Stifel lowered the firm’s price target on GE HealthCare (GEHC) to $80 from $98 and keeps a Buy rating on the shares. The list of positives underpinning GE HealthCare’s Q1…
GE HealthCare falls -13.4%
GE HealthCare (GEHC) is down -13.4%, or -$9.21 to $59.29.
GE HealthCare Technologies Earnings Call Transcript: Q1 2026
Q1 revenue grew 2.9% year-over-year to $5.1B, with strong global demand but profit pressured by inflation and a supplier recall. Guidance for 2026 EPS and margins was reduced, but sales growth and innovation momentum remain strong.
GE HealthCare cuts annual profit forecast as inflation weighs on costs
Medical equipment maker GE HealthCare on Wednesday cut its full-year profit forecast on the back of inflation-driven cost pressures, sending its shares down more than 9% in premarket trading.
GE HealthCare Cuts Outlook as Chip, Oil Prices Surge
GE HealthCare Technologies cut its profit outlook for the year after prices for memory chips, oil and freight jumped during the recent quarter.
GE HealthCare reports Q1 adjusted EPS 99c, consensus $1.05
Reports Q1 revenue $5.1B, consensus $5.03B. GE HealthCare (GEHC) President and CEO Peter Arduini said, “As we start the year, we’re pleased with topline performance, which came in at the…
GE HealthCare announces executive leadership updates
GE HealthCare (GEHC) announced a strategic evolution to its operations and executive leadership team to help shape the company’s next chapter of growth and better serve patients and customers globally...
GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company's next chapter of growth and bett...
GE HealthCare reports first quarter 2026 financial results
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the first quarter ended March 31, 2026. GE HealthCare President and CEO Peter Arduini said, “As we start the...
GE HealthCare management to present at upcoming investor conferences
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. Bank of America's 2026 Health Care...
GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial
GE HealthCare (GEHC) announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging contrast agent, man...
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation.
GE HealthCare price target lowered to $88 from $96 at Piper Sandler
Piper Sandler lowered the firm’s price target on GE HealthCare (GEHC) to $88 from $96 and keeps an Overweight rating on the shares. The firm is adding the recent acquisition…
GE HealthCare expands mammography collaboration with DeepHealth
GE HealthCare (GEHC) announced an expanded collaboration with DeepHealth, a player in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (RDNT), to further the innovation, com...